ArticleNature methods2019
T cell antigen discovery via signaling and antigen-presenting bifunctional receptors.
Open access · greenAbstract read
In one paragraph
Article in Nature methods, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers.
0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 152 citations in OpenAlex.
- Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma.The Journal of clinical investigation · 2022Trial
- Entering the Age of Specificity in T Cell Immunity.Immunological reviews · 2026Review
- Hybrid Insulin Peptides as Antigens and Tolerogens for Pathogenic T Cells in Autoimmune Diabetes.Immunological reviews · 2026Review
- Capturing the dynamics of STAT6 macrophage polarization using bioluminescence temporal signatures.Cell systems · 2026Article
- Unbiased avidity-based isolation of antigen-specific T cells.Journal for immunotherapy of cancer · 2026Article
- A Deep Learning-Driven Framework Integrating Organoid-Based Functional Validation Identifies Universal Neoantigens from Recurrent Glioma Mutations.Cancer research · 2026Article
- Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nature reviews. Immunology · 2026Review
- Coincident epithelial signals restrain commensal-specific CD8αβbioRxiv : the preprint server for biology · 2026Article
- Article
- TIRTL-seq: deep, quantitative and affordable paired TCR repertoire sequencing.Nature methods · 2026Article
- T Cell Antigen Discovery Using Cell-Based Epitope Libraries.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Molecular Mechanisms Behind Organ-Related Aging and Regulatory Effects of Natural Therapeutics.Cell biochemistry and biophysics · 2025Review
- Article
- Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.Chinese medical journal · 2025Review
- THLANet: A deep learning framework for predicting TCR-pHLA binding in immunotherapy applications.PLoS computational biology · 2025Article
- GRAPE: graph-regularized protein language modeling unlocks TCR-epitope binding specificity.Briefings in bioinformatics · 2025Article
- T cell receptor cross-reactivity prediction improved by a comprehensive mutational scan database.Cell systems · 2025Article
- Development of an innovative approach for early diagnosis of cervical cancer using TCR‑like antibodies targeting HPV18 E6 and E7 peptides.Molecular medicine reports · 2025Article
- Review
- Polymerised superparamagnetic antigen presenting cell lymphocyte capture for enriching tumour reactive T-cells and neoantigen identification.Nature communications · 2025Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Alok V JoglekarDepartment of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA. alokvj@caltech.edu.ORCID http://orcid.org/0000-0001-7554-7447
Michael T LeonardDepartment of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID http://orcid.org/0000-0001-9084-2647
John D JeppsonDepartment of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Margaret SwiftDepartment of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Guideng LiDepartment of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID http://orcid.org/0000-0003-0840-7262
Stephanie WongDepartment of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Songming PengDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, USA.
Jesse M ZaretskyDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
James R HeathDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, USA.
Antoni RibasDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Michael T BethuneDepartment of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
David BaltimoreDepartment of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA. baltimo@caltech.edu.ORCID http://orcid.org/0000-0001-8723-8190
California Institute of Technology · USUniversity of California, Los Angeles · US
Funding
UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9MRepurposing of cancer therapeutics for treatment of patients with COVID-19 diseaseU54CA199090 · NCI · INSTITUTE FOR SYSTEMS BIOLOGY · PI HEATH, JAMES R., RIBAS, ANTONI · 2015 to 2020
$11.4MNext Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4MNCI NIH HHS R35 CA197633NCI NIH HHS U54 CA199090NIGMS NIH HHS T32 GM008042
Abstract
CD8
Indexed as
Antigen PresentationSignal TransductionAntigen-Presenting CellsAntigensAntigens, CDAntigens, Differentiation, T-LymphocyteCD69 AntigensCD8-Positive T-LymphocytesCloning, MolecularCoculture TechniquesEpitopesFalse Positive ReactionsGene LibraryGreen Fluorescent ProteinsHEK293 CellsHumansAntigensAntigens, CDAntigens, Differentiation, T-LymphocyteCD69 AntigensEpitopesGreen Fluorescent ProteinsLectins, C-TypeOligonucleotidesPeptidesReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.